There’s more near-term competition looming however, with Biogen and Alkermes’ follow-up to Tecfidera – BIIB098 (diroximel fumarate) – due for an FDA verdict by the end of the year.

Orally-active S1P agonist Zeposia (ozanimod) has been submitted to the FDA as a treatment for adults with moderately to severely active ulcerative colitis (UC), with a decision from the US ...